Internet Archive Scholar

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis

María Sereno, Ana María Jimenez-Gordo, Javier Baena-Espinar, Carlos Aguado, Xabier Mielgo, Ana Pertejo, Rosa Álvarez-Álvarez, Ana Sánchez, Jose Luis López, Raquel Molina, Ana López-Alfonso, Berta Hernández (+8 others)
2021 Cancers  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.3 MB)
https://web.archive.org/web/20210903224459/https://mdpi-res.com/d_attachment/cancers/cancers-13-04205/article_deploy/cancers-13-04205-v2.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Approximately 15% of patients infected by SARS-CoV-2 develop a distress syndrome secondary to a host hyperinflammatory response induced by a cytokine storm. Myelosuppression is associated with a higher risk of infections and mortality. There are data to support methods of management for neutropenia and COVID-19. We present a multicenter experience during the first COVID-19 outbreak in neutropenic cancer patients infected by SARS-CoV-2. Methods: Clinical retrospective data were collected from
more » ... tropenic cancer patients with COVID-19. Comorbidities, tumor type, stage, treatment, neutropenia severity, G-CSF, COVID-19 parameters, and mortality were analyzed. A bivariate analysis of the impact on mortality was carried out. Additionally, we performed a multivariable logistic regression to predict respiratory failure and death. Results: Among the 943 cancer patients screened, 83 patients (11,3%) simultaneously had neutropenia and an infection with COVID-19. The lungs (26%) and breasts (22%) were the primary locations affected, and most patients had advanced disease (67%). In the logistic model, as adjusted covariates, sex, age, treatment (palliative vs. curative), tumor type, and the lowest level of neutrophils were used. A significant effect was obtained for the number of days of G-CSF treatment (OR = 1,4, 95% CI [1, 1, 03, 92], p-value = 0.01). Conclusions: Our findings suggest that a prolonged G-CSF treatment could be disadvantageous for these cancer patients with infections by COVID-19, with a higher probability of worse outcome.
doi:10.3390/cancers13164205 fatcat:2lwsmn4y3fbc7mim6frkx2sn2e
DOAJ
Citation

María Sereno, Ana María Jimenez-Gordo, Javier Baena-Espinar, Carlos Aguado, Xabier Mielgo, Ana Pertejo, Rosa Álvarez-Álvarez, Ana Sánchez, Jose Luis López, Raquel Molina, Ana López-Alfonso, Berta Hernández, Luis Enrique Chiara, Ana Manuela Martín, Ana López-Martín, Miriam Dorta, Ana Collazo-Lorduy, Enrique Casado, Ana Ramirez de Molina, Gonzalo Colmenarejo. "A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis." Cancers 13.16 (2021) 4205